PIK3CA and nonpapillary renal cell carcinoma: Examples of drugs that might be repurposed for treating ccRCC include: Temsirolimus, which is undergoing ongoing trials as a treatment for FBXW7-positive solid tumours65,66, nilotinib for ABL1 mutations67, niraparib for BAP1 mutations68, Tazemetostat hydrobromide for SMARCA4 mutated cancers69,70, olaparib with pembrolizumab for ARID2-positive melanoma71, and alpelisib for PIK3CA in ER-positive metastatic breast cancer72,73.